"DelveInsight’s, “Chronic Myeloid Leukemia Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myeloid Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Myeloid Leukemia Understanding

Chronic Myeloid Leukemia Overview

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. It's a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. The leukemia cells grow and divide, building up in the bone marrow and spilling over into the blood. In time, the cells can also settle in other parts of the body, including the spleen. CML is a fairly slow growing leukemia, but it can change into a fast-growing acute myeloid leukemia that's hard to treat.
CML does not usually cause any symptoms in its early stages and may only be picked up during tests carried out for another reason. As the condition develops, symptoms can include tiredness, weight loss, night sweats, tenderness and swelling in the left side of your tummy, feeling full after small meals, pale skin and shortness of breath and a high temperature.

Many people with chronic myeloid leukemia (CML) don't have symptoms when it's diagnosed. Doctor may do more tests to confirm the diagnosis, such as:

Complete blood count: It's a blood test that checks to see how many white blood cells, red blood cells, and platelets patient has.
Bone marrow test: It helps to figure out how advanced the cancer is. Doctor uses a needle to take a sample, usually from hip bone.
FISH test (fluorescence in situ hybridization): It's a detailed lab test of the genes.
Ultrasound or CT scans: They can check the size of spleen. Ultrasounds use sound waves to make images that doctors and other medical professionals can read. A CT is an X-ray that takes a series of pictures inside person’s body.
Polymerase chain reaction test: It's a lab test that looks for the BCR-ABL gene, which is involved in the process that tells the body to make too many of the wrong kind of white blood cells.
Chronic myeloid leukemia (CML) risk factors include genetic and environmental influences. Exposure to high doses of ionizing radiation, such as radiation therapy or nuclear accidents, increases risk. Older age and male sex are also associated with a higher likelihood of developing CML. While most cases are not inherited, certain genetic abnormalities, like the
Philadelphia chromosome (BCR-ABL1 fusion), drive the disease. Lifestyle factors have a limited role, and the exact cause in many patients remains unknown.

The goal of the treatment is to destroy the leukemia blood cells in the body and restore healthy ones to a normal level. It's usually not possible to get rid of all the bad cells. If the patient gets the treatment during the early, chronic phase of CML, it can help prevent the disease from moving to a more serious level. Doctors often use targeted therapy drugs that block the abnormal protein responsible for the disease. In some cases, treatments such as chemotherapy, stem cell transplant, or immunotherapy may also be recommended depending on the patient’s condition. Regular monitoring through blood tests is important to check how well the treatment is working.

"Chronic Myeloid Leukemia Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Myeloid Leukemia pipeline landscape is provided which includes the disease overview and Chronic Myeloid Leukemia treatment guidelines. The assessment part of the report embraces, in depth Chronic Myeloid Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Myeloid Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Chronic Myeloid Leukemia pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Chronic Myeloid Leukemia Report Highlights

The Chronic Myeloid Leukemia companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myeloid Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Myeloid Leukemia.

Chronic Myeloid Leukemia Emerging Drugs Analysis

This Chronic Myeloid Leukemia segment of the Chronic Myeloid Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Myeloid Leukemia Emerging Drugs

RS-5614: Renascience

RS‑5614 is an investigational therapy being developed by Renascience for the treatment of CML. RS5614 has passed all non-clinical safety tests required for clinical trials and manufacturing and sales as a drug. In addition, RS5614 has been administered to nearly 400 subjects (healthy people, chronic myeloid leukemia, novel coronavirus lung injury, malignant melanoma, lung cancer, systemic sclerosis, etc.), and long-term administration for one year was also performed for chronic myeloid leukemia, but no problematic side effects due to RS5614 have been reported, and it is considered to be a highly safe drug. In the past, many pharmaceutical companies and bio start-ups, both in Japan and overseas, have been working on developing small molecule PAI-1 inhibitors, and some of the drugs have been reported to be effective in animal models of mice and rats. However, all of these were discontinued at an early stage of development, and our drug is the oral PAI-1 inhibitor currently in the human clinical stage. Currently the drug is in Phase III stage of development for the treatment of CML.

ABL001: Novartis Pharmaceuticals

ABL001 is an investigational targeted therapy developed by Novartis Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and other cancers. It is a small‑molecule allosteric inhibitor that specifically binds to the myristoyl pocket of the BCR‑ABL1 fusion protein, a key driver of CML. By targeting the BCR‑ABL1 oncoprotein through a distinct mechanism from traditional tyrosine kinase inhibitors, ABL001 aims to overcome resistance and improve disease control. The drug is being evaluated in clinical studies to assess its safety, tolerability, and efficacy in patients with CML, including those with resistant or refractory disease. Currently the drug is in Phase II stage of development for the treatment of CML.

ELVN-001: Enliven Therapeutics

ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 targets the ATP-binding site of the ABL1 kinase domain and binds to a unique P-loop “folded-in” active conformation of ABL1, creating a narrow selectivity tunnel against the broader kinome. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR-ABL mutation, which confers resistance to nearly all approved tyrosine kinase inhibitors (TKIs), as well as activity against mutations known to confer resistance to allosteric BCR-ABL inhibitors. As per the company pipeline, the drug is in Phase I stage of its clinical trial for the treatment of Chronic Myeloid Leukemia.

MGD024: MacroGenics

MGD024 is an investigational bispecific DART® molecule being developed by MacroGenics for the treatment of chronic myeloid leukemia (CML) and other hematologic malignancies. It simultaneously engages CD123 on leukemic cells and CD3 on T‑cells, directing cytotoxic T‑cell activity against malignant cells. By harnessing the immune system, MGD024 aims to eliminate leukemic cells more effectively than conventional therapies. The drug is currently in early‑stage clinical development, with studies evaluating its safety, tolerability, and anti‑leukemic activity in patients with CML and related disorders.

Further product details are provided in the report……..

Chronic Myeloid Leukemia Therapeutic Assessment

This Chronic Myeloid Leukemia segment of the report provides insights about the different Chronic Myeloid Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Myeloid Leukemia

There are approx. 20+ key companies which are developing the therapies for Chronic Myeloid Leukemia. The companies which have their Chronic Myeloid Leukemia drug candidates in the most advanced stage, i.e. Phase III include, Renascience.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

Chronic Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Chronic Myeloid Leukemia Product Type

Chronic Myeloid Leukemia Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Myeloid Leukemia Clinical Trials Activities

The Chronic Myeloid Leukemia Pipeline report provides insights into Chronic Myeloid Leukemia Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses the Chronic Myeloid Leukemia key players involved in developing key drugs.

Chronic Myeloid Leukemia Pipeline Development Activities

The Chronic Myeloid Leukemia Pipeline report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Myeloid Leukemia drugs.

Chronic Myeloid Leukemia Report Insights

Chronic Myeloid Leukemia Pipeline Analysis
Chronic Myeloid Leukemia Therapeutic Assessment
Chronic Myeloid Leukemia Market Unmet Needs
Impact of Chronic Myeloid Leukemia Drugs

Chronic Myeloid Leukemia Report Assessment

Chronic Myeloid Leukemia Pipeline Product Profiles
Chronic Myeloid Leukemia Therapeutic Assessment
Chronic Myeloid Leukemia Pipeline Assessment
Inactive Chronic Myeloid Leukemia drugs assessment
Chronic Myeloid Leukemia Market Unmet Needs

Discover actionable insights into the Chronic Myeloid Leukemia market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered in the Chronic Myeloid Leukemia Pipeline Report

Current Treatment Scenario and Emerging Therapies:

How many Chronic Myeloid Leukemia companies are developing Chronic Myeloid Leukemia drugs?
How many Chronic Myeloid Leukemia drugs are developed by each company?
How many Chronic Myeloid Leukemia emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Myeloid Leukemia?
What are the Chronic Myeloid Leukemia key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Myeloid Leukemia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Myeloid Leukemia and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players

Renascience
Novartis Pharmaceuticals
AOP Orphan Pharmaceuticals GmbH
ImmunoForge
Enliven Therapeutics
MacroGenics

Key Products

RS5614
ABL001
Ropeginterferon alfa-2b
KF 1601
ELVN-001
MGD024

Explore comprehensive insights into Chronic Myeloid Leukemia epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.